01 March 2006
Glutathione metabolism of filarial worms: A vulnerable target for the designand synthesis of new antifilarial agents.
Sapna Gupta, Arvind Kumar SrivastavaMed Sci Monit 2006; 12(3): HY1-9 :: ID: 447100
Abstract
The main problem regarding the chemotherapy of filariasis is that no safeand effective drug is available yet to combat the adult human filarial worms. One of the main reasonsis the prolonged existence, i.e. survival of filarial worms in mammalian hosts for many years, and havinga very strong antioxidant system. Glutathione (GSH) has been identified as an important part of the antioxidantsystem of many, if not all, living cells and, together with glutathione reductase (GR), it maintainsthe correct intracellular redox balance. It protects the cell against oxidative damage by non-enzymaticscavenging of free radicals and by enzymatic neutralization of toxic hydrogen peroxide, lipid hydroperoxides,and derivatives by glutathione-dependent peroxidases (GPXs) and glutathione-S-transferases (GSTs). Workin this direction reveals that filarial worms can synthesize and recycle GSH, and its depletion may beuseful in chemotherapeutic situations in which the cells to be killed and the cells to be spared havesubstantially different quantitative requirements for GSH. All normal mammalian cells have a considerableamount of GSH, whereas filarial worms may have GSH concentrations close to that required for their survivaland, therefore, a little manipulation of the glutathione metabolism of filarial worms may have drasticconsequences. The present review details the application of the glutathione metabolism of filarial wormsas a target for the design and synthesis of new antifilarial agents.
Keywords: Filaricides - chemistry, Filariasis - drug therapy, Antioxidants - metabolism, Filarioidea - metabolism, Glutamate-Cysteine Ligase - metabolism, Glutathione - metabolism, Glutathione Peroxidase - metabolism, Glutathione Reductase - metabolism, Glutathione Transferase - metabolism, Models, Biological
Editorial
01 May 2024 : Editorial
Editorial: First Regulatory Approval for Adoptive Cell Therapy with Autologous Tumor-Infiltrating Lymphocytes (TILs) – Lifileucel (Amtagvi)DOI: 10.12659/MSM.944927
Med Sci Monit 2024; 30:e944927
In Press
14 Mar 2024 : Clinical Research
Renal Dysfunction Increases Risk of Adverse Cardiovascular Events in 5-Year Follow-Up Study of Intermediate...Med Sci Monit In Press; DOI: 10.12659/MSM.943956
15 Mar 2024 : Clinical Research
Impact of One-Lung Ventilation on Oxygenation and Ventilation Time in Thoracoscopic Heart Surgery: A Compar...Med Sci Monit In Press; DOI: 10.12659/MSM.943089
14 Mar 2024 : Clinical Research
Differential DHA and EPA Levels in Women with Preterm and Term Births: A Tertiary Hospital Study in IndonesiaMed Sci Monit In Press; DOI: 10.12659/MSM.943895
15 Mar 2024 : Clinical Research
Evaluation of an Optimized Workflow for the Radiofrequency Catheter Ablation of Paroxysmal Atrial FibrillationMed Sci Monit In Press; DOI: 10.12659/MSM.943526
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952